Profiling microvesicle nucleic acids and uses thereof as signatures in diagnosis of renal transplant rejection

The invention relates generally to the use of microvesicle RNA signatures for diagnosis, predicting, and/or to monitor treatment efficacy, including patients who are candidates for renal transplant and/or who have received a renal transplant.